Repurposing of Linagliptin and Similar FDA Approved Drugs as Antidiabetic Agents
May 2021
in “
Letters in Applied NanoBioScience
”
Studysummary This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on doi.org →